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Abstract
Human parechoviruses (HPeV) cause symptoms ranging from severe neonatal infections to mild gastrointestinal and respiratory
disease. Use of PCR and genotyping has markedly improved the detection rate of HPeV but has simultaneously raised questions about
the clinical relevance of positive tests. This retrospective study correlates positive HPeV1 or HPeV3 PCR tests in stools from children
with their symptoms to determine clinical relevance. Children with HPeV1- or HPeV3-positive stool samples, as detected by real time
RT-PCR and direct genotyping, between 2004 and 2008 were selected. Clinical data were retrospectively collected from the patient’s
ﬁles and results were compared. One hundred and thirty-eight children with positive HPeV1 (n = 112) or HPeV3 (n = 26) stool
samples were identiﬁed. Signiﬁcantly more HPeV3-infected children were neonates or infants younger than 6 months of age. Meningitis
or sepsis-like illnesses were diagnosed most frequently and were found in signiﬁcantly younger children. Almost half of HPeV1-infected
children had an underlying disease. Mild gastrointestinal disease was seen most frequently in these children. There was no clear
correlation between viral load (Ct value) and severity of symptoms. In conclusion, HPeV3 detected by PCR in stool samples is
associated with clinically relevant disease. For HPeV1, a positive stool sample is mainly associated with symptoms in children with
underlying disease.
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Introduction
Human parechovirus (HPeV) is increasingly recognized as an
important cause of sepsis-like illness (SLI) and meningitis in
young children [1,2]. There are 16 known HPeV types, of
which HPeV1 and HPeV3 are the most prevalent [3,4]. Like
enteroviruses, HPeV can cause a wide range of symptoms and
disease from mild gastrointestinal or respiratory disease to
SLI and meningitis. HPeV1 and HPeV2 usually evoke mild
gastrointestinal and respiratory symptoms, but occasionally
HPeV1 infection can elicit severe disease, such as encephalitis,
transient paralysis and myocarditis in children [5–7].
Human parechovirus type 3 was ﬁrst detected in 2004 in
Japan [8] and is associated with neonatal SLI and meningitis in
several studies [9–11].
The recently identiﬁed HPeV4, -5 and -6 [12–14] seem to
be associated with mild respiratory and gastrointestinal
symptoms [15], but the number of described cases is still
low. Clinical data on HPeV7–16 infections are rare or lacking.
Previously, we and others showed that HPeV3 infection is
associated with SLI and meningitis and that HPeV3-infected
children are signiﬁcantly younger than HPeV1-infected children
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[4,9]. The number of patients in these initial studies was small
and virus was detected by conventional cell culture from stool.
The clinical relevance of the presence of HPeV3 in cerebro-
spinal ﬂuid (CSF) was clearly demonstrated [2,10,16].
The use of PCR and direct genotyping has increased the
detection frequency of HPeV in stool samples [3,17,18];
however, the clinical relevance of PCR detection in stool
samples is still unknown. Although some show associations
between HPeV1 presence in stool samples and gastrointestinal
symptoms [18], others suggest that HPeV positivity in stool is
of little clinical importance and is an innocent bystander [19].
In this retrospective study we describe the demographic,
clinical and microbiological characteristics of a large group of
children with HPeV1 and HPeV3 infections. Correlations
between positive PCR ﬁndings and clinical symptoms and
between viral load in stool and severity of disease are
determined.
Materials and Methods
Detection of HPeV-positive patients by real-time RT-PCR
and genotyping
At the Laboratory of Clinical Virology of the Academic Medical
Centre in Amsterdam, the Netherlands, stool samples that had
been routinely stored at 80°C between January 2004 and
December 2006 were retrospectively screened for HPeV using
an HPeV-speciﬁc real-time RT-PCR [3,17], using a standardized
amount of stool. Stool samples obtained from 2007 onward
were prospectively screened as part of routine diagnostics by
the real-time RT-PCR. All stool samples were tested for
suspected viral infections (enterovirus and/or HPeV) as indi-
cated by the treating paediatrician, even in the absence of
gastrointestinal symptoms. The Ct value of the real-time
RT-PCR was used as a semi-quantitative read-out. A Ct value
>40 was considered negative [3,20,21]. Direct genotyping was
performed on all HPeV-positive stool samples by sequencing
the complete VP1 region, as described by Benschop et al. [3,17].
For this study, children with HPeV1- and HPeV3-positive
stool samples who visited the Academic Medical Centre (a
tertiary academic hospital) or the Amstelland Hospital Am-
stelveen (a general regional hospital) between January 2004 and
December 2008 were selected. The Academic Medical Centre
is a referral hospital for children with complex diseases, and it
also serves as a general hospital for their region.
Clinical data
Data on clinical signs and symptoms of children infected with
HPeV were retrospectively collected from the patient ﬁles.
The child’s age at time of HPeV detection, gender and
duration of hospital stay were documented. An infection was
labelled as hospital-acquired when the HPeV-positive stool
sample was obtained >6 days after hospital admission. Medical
records and letters of discharge at time of HPeV detection in
stool samples were used to collect data on the presence and
duration of fever (temperature >38.5°C), SLI (signs of
circulatory and/or respiratory dysfunction deﬁned by tachy-
cardia or bradycardia, low blood pressure and/or decreased
saturation), neurological symptoms (irritability, meningitis
(deﬁned as >19 leucocytes/μL in CSF for children aged 0–
28 days and >9 leucocytes/μL for children aged 29 days and
older [22] with or without elevated protein level (>0.35 g/L)
and/or decreases in glucose level (<2.8 mM) and/or positive
HPeV PCR), encephalitis, seizures or paralysis), gastrointesti-
nal symptoms (diarrhoea, nausea and/or vomiting), respiratory
symptoms (rhinorrhoea, cough, otitis, tonsillitis, signs of
dyspnoea, tachypnoea, wheezing, inspiratory stridor and
abnormalities on chest radiography), skin symptoms, use of
antibiotics and diagnosis at discharge. If a speciﬁc symptom
was not clearly mentioned in the medical record or letter of
discharge, the symptom information was labelled as ‘missing’.
Available laboratory results of blood (leucocyte count and
C-reactive protein) and CSF analysis (cell count, protein and
glucose level), results of neuro-imaging (cranial ultrasound,
computed tomography, magnetic resonance imaging) and the
presence and site of isolation of other micro-organisms were
also recorded. A ﬁnal diagnosis was made for every child based
on available clinical data. Patients were divided into ﬁve
categories: gastroenteritis, severe infection, respiratory tract
infection, infection not otherwise speciﬁed and other. Infection
not otherwise speciﬁed was deﬁned as a suspected viral illness
with or without fever and no clear localizing symptoms and
reported as such by the treating paediatrician. Other was used
to categorize all non-infectious diagnoses.
Statistical analysis
Data were analysed using SPSS for Windows, version 19/20.
Clinical symptoms were compared using a chi square test.
Differences betweenmeanswere compared using Student’s t test
and one-way analysis of variance or Kruskall–Wallis and Mann–
Whitney U test. A p value <0.05 was considered to be signiﬁcant.
Results
Patient characteristics
During the study period of 5 years, 138 children with
positive HPeV1 or HPeV3 stool samples were identiﬁed.
HPeV1 was found in 112 patients and HPeV3 was found in 26
patients (Table 1). One patient was infected with both types
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subsequently (HPeV3 at the age of 3 weeks and HPeV1 at
the age of 2.5 months).
In both groups, boys were more frequently infected with
either HPeV1 or HPeV3 than girls (Table 1, HPeV1 59%,
HPeV3 65%).
Signiﬁcantly more HPeV3-infected children were
<6 months at the time of diagnosis (p <0.05), with a median
age of 2 months at the time of HPeV3 diagnosis compared
with 6 months for children with an HPeV1 infection. Of the
HPeV3-infected children, 15.4% were neonates (younger than
28 days), whereas only 2.7% of the HPeV1-infected children
were younger than 28 days (p <0.05).
Almost half of the children (45%) with HPeV1 infection had
an underlying disease compared with only 12% of HPeV3-in-
fected children (p <0.05). Most children had cardiorespiratory
disease (21%), followed by gastrointestinal disease (15%) and
neurological disease (13%).
Hospital-acquired infections were not signiﬁcantly more
often found in children with HPeV1 infections. The proportion
of children that were not admitted to the hospital was 19% in
HPeV1-infected children and 28% in HPeV3-infected children.
However, children with an HPeV1 infection were admitted for
longer than HPeV3-infected children (median 9 versus 5 days).
Other pathogens were found in 37% of the HPeV1-positive
children and in 20% of the HPeV3-positive children (Table 1).
In the HPeV3 group, co-infection with enterovirus was seen in
the majority of patients. Viruses were also the most frequently
detected co-pathogens in the HPeV1 group, especially rotavi-
rus and enterovirus.
More than half (52%) of the children infected with HPeV3
received antibiotics whereas one-third of HPeV1-infected
children received antibiotics (p 0.07).
Infections with HPeV1 were found all year round, whereas
HPeV3 was detected exclusively in summer and autumn.
HPeV3 was found biannually in the years 2004, 2006 and 2008,
whereas HPeV1 was detected annually (Fig. 1).
Clinical characteristics; HPeV3 is associated with more
severe disease
Clinical data were available for the majority of the children
(Table 2).
Gastrointestinal symptoms were most frequently reported
and were found more often in children with HPeV1 infection
than in HPeV3-infected children (95 versus 77%, p <0.05).
Fever was recorded equally in both groups. Signiﬁcantly
more children with an HPeV3 infection had neurological
symptoms (33 versus 8%, p <0.05) or sepsis-like illness (24
versus 5%, p <0.05) as compared with HPeV1-infected
children. HPeV PCR was performed on blood in only nine
children with HPeV1 (four HPeV PCR-positive) and in two
Characteristic
HPeV with and without
co-infection
HPeV without
co-infection
HPeV1 HPeV3 HPeV1 HPeV3
Number of children (%) 112 (81) 26 (19) 71 (78) 20 (22)
Academic Medical Centre (%) 85 (85) 15 (15) 57 (84) 11 (16)
Amstelland Hospital (%) 27 (71) 11 (29) 14 (61) 9 (39)
Gender: Male (%) 66 (59) 17 (65) 39 (55) 13 (65)
Age at time of diagnosis (months)
Median (range) 6 (0–66) 2 (0–30) 6 (0–54) 2 (0–30)
<6 months (%) 48 (43) 18 (69)* 34 (48) 14 (70)
Neonate (%) 3 (3) 4 (15)* 1 (1) 4 (20)*
Underlying disease (%)a 50/112 (45) 3/25 (12)* 35/71 (49) 2/20 (10)*
Prematurity (%)a 14/111 (13) 4/25 (16) 9/70 (13) 2/20 (10)
Presentation with suspected
infection (%)a
71/109 (65) 21/25 (84) 41/70 (59) 16/20 (80)
Hospital-acquired infection (%)a 23/112 (21) 3/25 (12) 15/71 (21) 3/20 (15)
Not admitted (%)a 21/111 (19) 7/25 (28) 17/71 (24) 5/20 (25)
Duration of hospitalization (days)
Median (range) 9 (1–276) 5 (2–80) 9 (1–276) 5 (2–80)
Antibiotics given (%)a 35/107 (33) 13/25 (52) 19/68 (28) 9/20 (45)
Other microorganism detected
(%)a
41/112 (37) 5/25 (20)
Faeces Enterovirus 11 4
Rotavirus 15 0
Adenovirus 1 0
Bacteria 4 0
Parasite 0 1
Blood Bacteria 4 0
Parasite (malaria) 1 0
Cerebrospinal ﬂuid Bacteria 2 0
Nasopharyngeal aspirate Enterovirus 1 0
Other virus 7
Sputum Bacteria 2 0
Abdominal drain ﬂuid Bacteria 1 0
aData are displayed as number of children with characteristic/number of children of which presence or absence of
characteristic is known.
*p <0.05 for comparison between HPeV1- and HPeV3-positive children.
TABLE 1. Characteristics of children
with positive stool samples for human
parechovirus type1 (HPeV1)or type3
(HPeV3)
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children with HPeV3-positive stool samples (both HPeV
PCR-positive).
The HPeV PCR was performed on CSF samples of 13
children (ﬁve HPeV3 and eight HPeV1) with a clinical suspicion
of meningitis. None of the eight HPeV1-positive children had a
positive HPeV PCR in CSF whereas all ﬁve children with
HPeV3 had a positive HPeV PCR in CSF. Other pathogens
were found in the CSF of two of the HPeV1-positive children
(Streptococcus pneumoniae in a previously healthy child and a
coagulase-negative Staphylococcus in a child with a ventricu-
lo-peritoneal drain).
In HPeV1-positive children an elevated white blood cell
count was recorded in 67% of nine CSF specimens available for
cell count. None of the children with HPeV3 had an elevated
CSF white blood cell count (of three CSF specimens available
for cell count).
Skin symptoms were signiﬁcantly more common in
HPeV3-infected children compared with HPeV1-infected chil-
dren (38 versus 9%, p <0.05). Exanthema was most frequently
described in HPeV3-positive children.
Respiratory symptoms were seen more frequently in
children with HPeV1 (41%) versus HPeV3-infected children
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FIG. 1. Prevalence of human parechovirus type 1 (HPeV1) and type 3 (HPeV3) in various months and years.
TABLE 2. Clinical symptoms of
children with human parechovirus
type 1 (HPeV1) and type 3 (HPeV3)
infection Clinical symptoms
No. of patients with HPeV1 and HPeV3
infection with and without other
co-infections (%)
No. of patients with HPeV1 and
HPeV3 infection without other
co-infections (%)
HPeV1 HPeV3 Total HPeV1 HPeV3 Total
Fever 47/106 (44) 12/24 (50) 59/130 (45) 23/67 (34) 10/19 (53) 33/86 (38)
Sepsis-like illness 5/107 (5) 6/25 (24)* 11/132 (8) 1/68 (1) 5/20 (25)* 6/108 (6)
Neurological symptoms 8/104 (8) 8/24 (33)* 16/128 (13) 4/67 (6) 6/19 (32)* 10/86 (12)
Meningitisa 6/8 5/5 3/6 3/3
Irritability 6/8 7/8 3/4 5/6
Convulsions 2/8 0/8 2/4 0/6
Gastrointestinal
symptoms
101/106 (95) 20/26 (77)* 121/132 (92) 65/67 (97) 16/20 (80)* 81/87 (93)
Diarrhoea 89/99 17/21 56/64 14/17
Blood in stools 12/88 1/20 7/56 1/16
Nausea/vomiting 52/97 4/20 27/62 3/16
Skin symptoms 9/104 (9) 9/24 (38)* 18/128 (14) 6/66 (9) 7/19 (37)* 13/85 (15)
Respiratory symptoms 42/103 (41) 3/24 (13)* 45/127 (35) 25/65 (39) 2/19 (11)* 27/84 (32)
Upper respiratory
tract symptoms
33/42 3/3 20/25 2/2
Otitis 14/38 0/3 9/24 0/2
Lower respiratory
tract symptoms
14/42 1/3 6/25 1/2
Data are displayed as number of children with documented symptom/number of children with documentation of
presence or absence of characteristic.
aDeﬁned as elevated white blood cell count in cerebrospinal ﬂuid (CSF) and/or HPeV PCR-positive in CSF.
*p <0.05 for comparison between HPeV1- and HPeV3-positive children.
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(13%, p <0.05), and were mainly described as upper respira-
tory tract symptoms. The HPeV PCR was performed on
nasopharyngeal aspirate in ten children with HPeV1-positive
stools (ﬁve HPeV PCR positive) and none of the children with
HPeV3-positive stools.
Overall, children with HPeV3 infection had signiﬁcantly
more severe disease (SLI and/or meningitis) as the ﬁnal
diagnosis in comparison with children with HPeV1 infection
(35% versus 3%, p <0.05, Table 3).
For children with an HPeV1 infection, gastroenteritis was
the most common ﬁnal diagnosis (71%). Most of these children
had mild gastroenteritis but were admitted for other reasons
or were diagnosed with HPeV1 while hospitalized for other
reasons. Severe gastroenteritis, leading to hospitalization was
only described in 17% of the children with detection of HPeV1
as a sole pathogen (Table 3).
To determine in what proportion of HPeV PCR-positive
stool samples symptoms were attributable to HPeV infection,
children with a non-infectious ﬁnal diagnosis (deﬁned as
‘other’ in Table 3) or the presence of another pathogen were
excluded. This resulted in 51% of the HPeV1-positive
children and 72% of the HPeV3-positive children with an
infection as ﬁnal diagnosis in whom HPeV was the only
pathogen found.
In the group of HPeV3-infected children, the mean age of
children with severe disease (3.7 months; SD  8.4 months)
or with an infection not otherwise speciﬁed (2.4 months;
SD  3.2 months) was signiﬁcantly lower than children with
gastroenteritis (16 months; SD  11.8 months). In the HPeV1
group there were no age-related differences in diagnosis.
No clear correlation between Ct value in stool and severity of
disease
To investigate whether viral load detected in stool by PCR was
correlated with severity of clinical symptoms, the Ct value of
the real-time 5′ untranslated region PCR was used as a
semi-quantitative read-out [20,21]. The overall mean Ct value
of the stool samples was low (indicating high viral loads) in
both HPeV1 (26.2  4.9 SD) and HPeV3 (26.7  4.1 SD)
-infected children (Fig. 2).
Stool samples with high Ct values are often difﬁcult to
culture [17] and are therefore considered of less clinical
relevance. Benschop et al. [17] found that the mean Ct value,
at which HPeV culture became negative but PCR remained
positive in faeces, was 35.
None of the HPeV3-infected children had a Ct value >35,
whereas eight of the HPeV1-infected children had Ct values of
>35. In the HPeV1-infected children there was no association
of Ct value with either ﬁnal diagnosis, presence of co-infection,
underlying disease or severity of symptoms.
Remarkably, in the group of HPeV3-infected children
without co-infection, Ct values were signiﬁcantly higher (mean
Ct value of 31.1  1.2 SD, range 30.1–33.0) in children
presenting with severe infection (SLI and/or meningitis),
compared with children with other diagnoses (mean Ct value
of 25.1  3.8 SD, range 18.7–32.3).
Final diagnosis
No. of patients with:
HPeV1 without
and with co-
infections (%)
HPeV1
without co-
infections (%)
HPeV3 without
and with co-
infections (%)
HPeV3
without co-
infections (%)
Gastroenteritis 75 (71) 47 (72) 6 (24)* 4 (20)*
Other reason for admittance,
during stay gastroenteritis
34 (32) 25 (39) 3 (12) 3 (15)
Gastroenteritis mild
(no admittance)
13 (12) 11 (17) 3 (12) 1 (5)
Gastroenteritis severe
(admittance)
28 (27) 11 (17) 0 0
Severe infection 8 (8) 2 (3) 9 (36)* 7 (35)*
SLI 3 (3) 2 (3) 4 (16) 4 (20)
Meningitis 0 0 2 (8) 1 (5)
SLI and meningitis 0 0 3 (12) 2 (10)
Bacterial sepsis and/or
meningitis
4 (4) 0 0 0
Pericarditis 1 (1) 0 0 0
Respiratory tract infection 5 (5) 1 (2) 0 0
Upper respiratory tract
infection
2 (2) 1 (2)
Lower respiratory tract
infection
3 (3) 0
Infection NOS 4 (4) 4 (6) 8 (32)* 7 (35)*
Other 13 (12) 11 (17) 2 (8) 2 (10)
Total 105 (100) 65 (100) 25 (100) 20 (100)
SLI, sepsis-like illness; infection NOS, infection not otherwise speciﬁed.
*p <0.05 for comparison between HPeV1- and HPeV3-positive children without and with co-infection and for
comparison between HPeV1- and HPeV3-positive children without co-infection.
TABLE 3. Final diagnosis of children
withhumanparechovirus type1 (HPe
V1) and type 3 (HPeV3) infection
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Discussion
In this study, we describe a comprehensive clinical analysis of
HPeV1-infected and HPeV3-infected children diagnosed by
real-time RT-PCR and direct genotyping of stool samples,
focusing on the relevance of PCR as a diagnostic method for
HPeV infection in stool samples. A positive HPeV3 stool
sample is, in the vast majority of cases, associated with relevant
clinical disease. HPeV1-positive stool samples are mainly of
clinical relevance in children with underlying disease.
In this large patient group diagnosed by PCR we conﬁrm
our previous results that infection with HPeV3 is signiﬁcantly
more associated with severe disease in younger children
compared with infection with HPeV1 [9]. Although those
results were based on virus detection by virus culture from
stool in a small group of patients, they were conﬁrmed by
other studies from Europe and North America [2,4,10,16,23–
25]. Our results also show that HPeV3-infected children with
severe disease are signiﬁcantly younger than HPeV3-infected
children with gastroenteritis. Earlier studies described that
more serious disease is usually seen in younger children [9–
11,23], but this study is the ﬁrst to show a signiﬁcant
difference.
In a study in Japanese children with HPeV infection detected
by PCR in stool samples, low numbers of severe disease in
both HPeV1- and HPeV3-infected children were found [18].
The age of the Japanese HPeV3-infected children was markedly
older (average 12.1 months) than the HPeV3-infected children
in this study. This is in agreement with our observation that
severe disease is seen in younger children.
Seroprevalence studies showed that 92–99% of adults have
antibodies against HPeV1 [26]. In children, seroprevalence of
HPeV1 is around 30% at the age of 1 year, increasing to >70%
at the age of 2 years [27], indicative of a high infection rate of
HPeV1 in young children. Seroprevalence of HPeV3 is low
(<2.7%) in children and does not increase much in adulthood
(10–13%) in Europe [26]. The absence of neutralizing HPeV3
antibodies in adults could be an explanation for the occurrence
of HPeV3 infection at very young ages with more severe
symptoms, as young children are not protected by maternal
antibodies.
The role of HPeV1 in causing clinical symptoms and disease
is yet to be determined. Although some studies [19,28,29]
report lack of associations between clinical symptoms and
HPeV1 detection, other studies [30] found associations
between HPeV1 infection and otitis media. As in earlier
studies [4,24] we found that HPeV1 infection is mainly
associated with (mild) gastroenteritis and detected mostly in
children with an underlying illness or in combination with
other pathogens, which corroborates that HPeV1 is of low
clinical importance and so can be seen as an innocent
bystander in certain cases, as suggested by Zhang et al. [19].
In accordance with earlier reports from the Netherlands,
we conﬁrm that HPeV1 is seen year round, with peaks in the
winter season, whereas HPeV3 is mainly seen in summer and
autumn [4,9]. Earlier studies from our centre showed that in
2004–2006 HPeV PCR was positive in 16.3% of stool samples
of children under the age of 5 years, with HPeV1 and HPeV3
being the most predominant types [3]. In 2007–2008 HPeV
PCR was positive in 8.6% of stool samples, detected mainly in
children under the age of 5 years [17].
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FIG. 2. Ct value in faeces and ﬁnal diagnosis of children infected with human parechovirus type 1 (HPeV1) and type 3 (HPeV3).
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In contrast with HPeV1, for which the prevalence was
relatively stable over the years, HPeV3 was almost exclusively
found in even calendar years as described before in the
Netherlands [3,4,23] and the UK [2]. Other studies in Europe
[16,25] and Japan [8,18] did not conﬁrm this bi-annual
circulation. Interestingly, in the USA HPeV3 is detected mainly
in the summer of uneven calendar years [10,11]. The
underlying reason for these differences remains unknown.
Conclusion
In a large group of HPeV-infected children we show that
HPeV3 detected by PCR in stool samples is associated with
younger age and more severe disease (SLI and/or meningitis)
and is clinically relevant when detected, regardless of Ct value.
HPeV1 is predominantly found in susceptible patients like
those with underlying disease or in combination with other
infectious pathogens. HPeV1 mainly elicits (mild) gastrointes-
tinal symptoms, and its detection in stool is of less clinical
relevance than HPeV3 detection.
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